http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021015870-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2703e7ca03aaf0c122f2f305afb47cd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a550434b6958ab2bcd7ef9425e44c2a6
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
filingDate 2020-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b8708cf9837f7f5f60bae91f5fd2160
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41000d8c46b097d1b3b5b1a2489259ee
publicationDate 2021-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2021015870-A1
titleOfInvention Bcma-car-t cells
abstract The present invention is directed to a monoclonal anti-human BCMA antibody, or a single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 6 and VL having the amino acid sequence of SEQ ID NO: 7. The present invention is also directed to a BCMA chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. The monoclonal antibody of the present invention exhibits selective and high-affinity binding to BCMA. BCMA CAR-T cells based on BCMA scFv of the present invention significantly decreases multiple myeloma tumor growth in an animal model.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021347850-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11643452-B2
priorityDate 2018-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399382
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6305
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID857
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399383
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405934
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1148
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2733531
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6140
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395985
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395986
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398727
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398728
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6106

Total number of triples: 48.